AMENDED AND RESTATED RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • August 28th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • New York
*** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED...Research, Option and License Agreement • June 9th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations • New York
This RESEARCH, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of April 15, 2015 (the “Effective Date”) by and between INTEC PHARMA LTD., with offices located at 12 Hartom St., P.O.B 45219, Jerusalem 91450 (“Intec Pharma”) and “[***]” with offices located at “[***]”, Massachusetts, “[***]” USA “[***]”. Each of Intec Pharma and “[***]” is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
RESEARCH, OPTION AND LICENSE AGREEMENTResearch, Option and License Agreement • December 23rd, 2015 • Clearside Biomedical, Inc. • Pharmaceutical preparations • Delaware
This Research, Option and License Agreement (hereinafter “Agreement”), effective as of April 27, 2015 (the “Effective Date”), is made by and between Spark Therapeutics, Inc., a Delaware corporation with corporate offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”) and Clearside Biomedical, Inc., a Delaware corporation with corporate offices at 1220 Old Alpharetta Rd., Suite 300, Alpharetta, GA 30005 (“Clearside”) (each, a “Party” and collectively, the “Parties”).
